Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBODY 2 phase 3 trial of epratuzumab in moderate to severe systemic lupus erythematosus
2010-018565-26Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Epratuzumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Week 48 combined response index response rate. Started Nov 2010; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-018565-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018565-26.